Peptide Terminal Modifications: Amides, Acetyl Caps and Your Spec
Two small chemical groups cause a surprising share of the identity questions that reach a QC desk. One sits at the start of a chain and one at the end. Peptide terminal modifications, mainly N-terminal acetylation and C-terminal amidation, change a molecule’s mass by very little but change its charge, its stability to enzymes and its behaviour on a column by a great deal. For a lab ordering the same sequence across many vials or lots, getting the terminal form written correctly into the specification is one of the cheapest ways to avoid a costly mismatch later.
The two ends of a chain
Every linear peptide has a free amine at its N-terminus and a carboxylic acid at its C-terminus, unless something has been done to them. Those groups ionise in water: near neutral pH the amine carries a positive charge and the acid a negative one. Capping either end removes that charge and alters the chemistry of the whole molecule.
The two modifications most often met in research catalogues are:
- C-terminal amidation, where the terminal –COOH becomes –CONH2.
- N-terminal acetylation, where the terminal –NH2 is converted into an acetamide (CH3CO–NH–).
Both occur in biology. Many endogenous signalling peptides are amidated by an enzyme that processes a glycine-extended precursor, and N-terminal acetylation is common on proteins made in eukaryotic cells. When a synthetic sequence is designed to match a natural one, or to resist degradation in an in-vitro system, these groups are built in deliberately.
Mass and charge: the numbers to know
| Modification | Change to monoisotopic mass | Change to charge near pH 7 | How it is written |
|---|---|---|---|
| C-terminal amide | about −0.984 Da versus the free acid | loses one negative charge | …-NH2 at the end |
| N-terminal acetyl | about +42.011 Da | loses one positive charge | Ac-… at the start |
| Pyroglutamate (from N-terminal Gln) | about −17.027 Da | loses one positive charge | pGlu- or <Glu at the start |
The acetyl shift is easy to see on any mass spectrum. The amide shift is not. Just under one dalton is also close to the spacing between isotope peaks, so an amidated peptide’s carbon-13 peak lands very near the free acid’s monoisotopic peak. Telling them apart reliably needs a resolving instrument and a comparison made on the same mass basis, monoisotopic against monoisotopic. Our guide to monoisotopic and average mass explains why mixing the two can hide exactly this difference, and mass accuracy in ppm covers how tight the measurement needs to be.
The pyroglutamate row is worth keeping in mind as an unintended terminal change. A glutamine at the N-terminus can cyclise on its own, releasing ammonia, and the resulting species is lighter and less basic than the parent.
Why designers cap the ends
Exopeptidases recognise free termini. Aminopeptidases trim from a free N-terminal amine and carboxypeptidases from a free C-terminal acid. A capped end is a poor substrate, so terminal modification is a standard tool for making an analog last longer in serum-containing or tissue-derived in-vitro systems.
Charge is the second reason. Removing a terminal charge makes the molecule a closer mimic of an internal segment of a protein, which matters when a short peptide is used to represent part of a larger structure. It also shifts the isoelectric point: amidation pushes it up, acetylation pushes it down. That in turn changes the pH at which the material is hardest to dissolve, as explained in our article on the peptide isoelectric point.
How the terminal form is decided during synthesis
In solid-phase synthesis the C-terminal form is largely fixed by the resin chosen at the start. An amide-generating resin releases the finished chain as the amide; an acid-generating resin releases the free acid. The N-terminal acetyl is added at the end of assembly by treating the resin-bound chain with an acetylating reagent before cleavage.
Acetylation also appears in another role. Many synthesis routines cap unreacted chains after each coupling, and those short, capped fragments are acetylated at the N-terminus too. On a mass spectrum of crude material they show up as truncated sequences carrying +42 Da. The solid-phase synthesis cycle article walks through where they come from.
Peptide terminal modifications on a certificate
The written sequence is not always a reliable guide. By convention, a sequence with no terminal notation is read as a free amine and a free acid, and some documents make this explicit with H- at the start and -OH at the end. In practice catalogue names often drop the notation entirely, and trade names never include it.
The calculated molecular formula and mass are the better guide. When checking a certificate, compare:
- the sequence notation, including Ac- and -NH2 where they apply;
- the molecular formula, which should contain one more nitrogen and one fewer oxygen for an amide than for the acid;
- the calculated mass, which should match the terminal form in the notation;
- the measured mass, compared against that calculated value on the same basis.
If the notation says amide but the calculated mass fits the free acid, or vice versa, raise it before the vials go into stock. The two forms are different compounds, with different registry entries and different chromatographic and charge behaviour, even though they share a residue sequence.
Writing the terminal form into a volume order
For multi-vial and repeat orders, a specification that names the terminal form removes ambiguity at every future reorder. A useful line includes the full sequence with both termini written out, the molecular formula, and the calculated monoisotopic mass. When lots arrive, log the measured mass for each one against that same target. Consistency across lots is then easy to see, and a lot supplied in the wrong terminal form is caught at receiving rather than midway through an experiment.
Bulk Peptides sends its products for third-party HPLC and purity testing. Certificates are posted for a number of products on the product pages or the certificates of analysis page, and vials carry cap and crimp colours that match them to their certificate.
All compounds discussed here are offered for laboratory research only. They are not drugs or supplements, and they are not for use in people or animals.
